Fee comparisons of treatments for nonmelanoma skin cancer in a private practice academic setting
- PMID: 22145798
- PMCID: PMC3839857
- DOI: 10.1111/j.1524-4725.2011.02231.x
Fee comparisons of treatments for nonmelanoma skin cancer in a private practice academic setting
Abstract
Objective: To compare fees for biopsy, treatment procedure, repair, and 2-month follow-up for nonmelanoma skin cancer (NMSC) treatments: electrodesiccation and curettage (ED&C), excision, and Mohs micrographic surgery (MMS).
Methods: A cost comparison of 936 primary NMSCs diagnosed in 1999/2000 at a University affiliated dermatology practice. Clinical data was from medical record review. 2007 Medicare Fee Schedule costs determined fees for surgical care. Pearson chi-square tests, t-tests and analysis of variance compared fee differences. Linear regression determined independent effects of tumor and treatment characteristics on fees.
Results: Mean fees/lesion were $463 for ED&C, $1,222 for excision, and $2,085 for MMS (p < .001). For all treatments, primary procedure costs were highest (38%, 45%, and 41%). Total repair fees were higher with MMS ($735) vs excisions ($197). Fees were higher for head and neck tumors (p < .001), H-zone tumors (p < .001), and tumors smaller than 10 mm in diameter (p = .04). Regression models predicted that the treatment fees would be $2,109 for MMS and $1,252 for excision (p < .001). Tumor size greater than 10 mm in diameter (added $128), tumors on the head and neck (added $966), and MMS (added $857 vs excision) were independently related to higher fees (p < .001).
Conclusion: Even after adjusting for risk factors, MMS has higher fees than excision for primary NMSC. Repairs accounted for the majority of this difference. These fee comparisons provide a basis for comparative effectiveness studies of treatments for this common cancer.
© 2011 by the American Society for Dermatologic Surgery, Inc. Published by Wiley Periodicals, Inc.
Figures
Similar articles
-
Cost effectiveness of Mohs micrographic surgery: review of the literature.J Drugs Dermatol. 2009 Oct;8(10):914-22. J Drugs Dermatol. 2009. PMID: 19852120 Review.
-
A relative value unit-based cost comparison of treatment modalities for nonmelanoma skin cancer: effect of the loss of the Mohs multiple surgery reduction exemption.J Am Acad Dermatol. 2009 Jul;61(1):96-103. doi: 10.1016/j.jaad.2008.07.047. J Am Acad Dermatol. 2009. PMID: 19539843
-
Surgical excision versus Mohs' micrographic surgery for primary and recurrent basal-cell carcinoma of the face: a prospective randomised controlled trial with 5-years' follow-up.Lancet Oncol. 2008 Dec;9(12):1149-56. doi: 10.1016/S1470-2045(08)70260-2. Epub 2008 Nov 17. Lancet Oncol. 2008. PMID: 19010733 Clinical Trial.
-
Mohs micrographic surgery and surgical excision for nonmelanoma skin cancer treatment in the Medicare population.Arch Dermatol. 2012 Apr;148(4):473-7. doi: 10.1001/archdermatol.2011.2456. Arch Dermatol. 2012. PMID: 22508870
-
Mohs' micrographic surgery for nonmelanoma skin cancers.Clin Plast Surg. 1997 Oct;24(4):705-18. Clin Plast Surg. 1997. PMID: 9342512 Review.
Cited by
-
Aging and the treatment of basal cell carcinoma.Clin Dermatol. 2019 Jul-Aug;37(4):373-378. doi: 10.1016/j.clindermatol.2019.06.004. Epub 2019 Jun 16. Clin Dermatol. 2019. PMID: 31345326 Free PMC article.
-
Same Day Biopsy and Treatment of Non-Melanoma Skin Cancer in Patients with Field Cancerization: A Retrospective Chart Study.J Skin Cancer. 2023 Feb 1;2023:9990046. doi: 10.1155/2023/9990046. eCollection 2023. J Skin Cancer. 2023. PMID: 36777100 Free PMC article.
-
Targeted Therapies Compared to Dacarbazine for Treatment of BRAF(V600E) Metastatic Melanoma: A Cost-Effectiveness Analysis.J Skin Cancer. 2015;2015:505302. doi: 10.1155/2015/505302. Epub 2015 Jun 10. J Skin Cancer. 2015. PMID: 26171248 Free PMC article.
-
Extramammary paget disease: minimal surgical therapy.Ann Dermatol. 2013 May;25(2):213-7. doi: 10.5021/ad.2013.25.2.213. Epub 2013 May 10. Ann Dermatol. 2013. PMID: 23717014 Free PMC article.
-
Response to Rogers et al.J Invest Dermatol. 2014 Apr;134(4):1136-1137. doi: 10.1038/jid.2013.451. Epub 2013 Oct 30. J Invest Dermatol. 2014. PMID: 24172599 No abstract available.
References
-
- Rogers HW, Weinstock MA, Harris AR, Hinckley MR, et al. Incidence estimate of nonmelanoma skin cancer in the United States, 2006. Arch Dermatol. 2010;146:283–7. - PubMed
-
- Chren MM, Sahay AP, Sands LP, Maddock L, et al. Variation in care for nonmelanoma skin cancer in a private practice and a Veterans Affairs clinic. Med Care. 2004;42:1019–26. - PubMed
-
- Malhotra R, Huilgol SC, Huynh NT, Selva D. The Australian Mohs database, part I: periocular basal cell carcinoma experience over 7 years. Opthalmology. 2004;111:631–6. - PubMed
-
- Malhotra R, Huilgol SC, Huynh NT, Selva D. The Australian Mohs database, part II: periocular basal cell carcinoma outcome at 5 year follow-up. Opthalmology. 2004;111:631–6. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical